Altoida

Enabling Early Detection for a Healthier Brain

Revolutionizing neurology diagnostics with our digital NeuroMarker Platform designed to rapidly detect early cognitive decline and empower healthcare providers to intervene sooner—when treatment is most effective.
Learn more about our platform

Current Diagnostics Miss Early Detection

Leading to Long Wait Times for Treatment Decisions

2,000

People per day progress to more advanced stages of Alzheimer’s disease.

20

U.S. states are “dementia neurology deserts” as shrinking provider networks and rising demand have created a critical neurologist shortage, labeled a “grave threat” by the American Academy of Neurology.

70+

Months a patient will wait from cognitive complaint to a treatment decision with current standard care by 2033. The current wait is 12 months.
Early detection of mild cognitive impairment (MCI) and Alzheimer’s is often delayed due to limited access to specialized diagnostics, leaving some patients waiting years for a diagnosis. Current standard of care, paper-based cognitive assessments can be subjective, misdiagnose up to 30% of cases and fail to capture subtle cognitive and functional changes, further delaying treatment decisions and hindering early intervention.  These challenges lead to significant delays in care, increasing the burden on patients, caregivers, and already overextended healthcare providers.

Advancing Early Detection for

Faster, More Effective Intervention

The aim of Altoida’s groundbreaking NeuroMarker Platform is to empower clinicians with real-time insights during a single office visit. Using machine learning and augmented reality to simulate instrumental activities of daily living (iADL), it is designed to detect the earliest signs of cognitive impairment. Developed for faster diagnosis, this platform is intended to help healthcare providers intervene sooner, giving millions of patients a better chance at receiving timely, effective treatment.

Discover our Platform

Pioneering

Early Detection in Cognitive Health

Our NeuroMarker Platform is built on two decades of rigorous, peer-reviewed clinical research and scientific validation. Through numerous clinical studies, it has been proven to be highly effective in identifying MCI and early signs of Alzheimer’s disease, our proprietary technology also has potential applications for other related dementias. Founded on robust clinical insights and continuous evidence generation, our mission is to empower healthcare providers with the tools they need to make earlier, more informed decisions in patient care.

Read our Latest Breakthroughs

Proven: Early & Accurate Detection of Prodromal Alzheimer's Disease

The Altoida NeuroMarker Platform can effectively identify preclinical and prodromal Alzheimer's disease quicker than traditional neuropsychological tests without any learning effects.
Read the RADAR-AD Study

The Vital Role of Diagnostics in

Advancing Alzheimer's Research

Explore recent studies that highlight how innovative diagnostics are driving breakthroughs in Alzheimer's diagnosis and treatment.

08.26.21

The Best Foods That Support Brain Health, Memory, and Concentration

Foods that support brain health, memory, and concentration often involve those that reduce or mitigate inflammation, which can be harmful to the brain.
08.24.21

The Neuropathological Hallmarks of Alzheimer’s Disease

Neuropathological hallmarks of Alzheimer’s disease include positive and negative lesions such as beta-amyloid plaques and neuronal and synaptic loss.
08.19.21

Effectively Communicating with Dementia Patients about Treatment Options

Effectively communicating with dementia patients about treatment options can be difficult. Here are best practices that can alleviate common challenges.
08.17.21

Digital Biomarkers for Alzheimer’s Disease: Early Diagnosis Means Early Treatment

Digital biomarkers for Alzheimer’s disease may enable early diagnosis and may facilitate access to early treatments and therapies for Alzheimer’s patients.
08.12.21

Aducanumab: Alzheimer’s Disease Treatment Options & What This Means Moving Forward

With the recent approval of Aducanumab for Alzheimer’s disease, early identification of Alzheimer’s is critical. Here’s what this means moving forward.
08.10.21

Patients Ask: Is There a Blood Test for Alzheimer’s Genes?

Is there a blood test for Alzheimer’s genes? When patients ask, here’s what you need to know from early-onset to late-onset Alzheimer’s disease.
1 … 22 23 24 25 26
More Resources

News

Shaping the Future of Cognitive Health

The latest coverage on our work. Explore how Altoida’s technology is shaping the future of early detection and transforming patient care.
1 … 22 23 24 25 26 … 31
View all News

Get in Touch with Us

Whether you have questions about our platform or want to explore partnership opportunities, we’re here to help. Our team is ready to provide you with the answers and support you need.